Zobrazeno 1 - 10
of 102
pro vyhledávání: '"Hideo SHIGEMATSU"'
Autor:
Noriko Goda, Shinsuke Sasada, Hideo Shigematsu, Norio Masumoto, Koji Arihiro, Hiroyoshi Nishikawa, Shimon Sakaguchi, Morihito Okada, Takayuki Kadoya
Publikováno v:
Discover Oncology, Vol 13, Iss 1, Pp 1-12 (2022)
Abstract Purpose FOXP3 + and CD8 + are recognized markers of tumor-infiltrating lymphocytes (TILs) for breast cancer. FOXP3 + TILs are composed of effector Tregs (eTregs) and other subpopulations that are classified by their differences in suppressiv
Externí odkaz:
https://doaj.org/article/70b346668fcf43289c7b737ddf251d88
Publikováno v:
World Journal of Surgical Oncology, Vol 17, Iss 1, Pp 1-8 (2019)
Abstract Background The prognostic value of sentinel lymph node (SLN) metastases may be minimized by the limited disease burden of lymph node metastases and tailoring adjuvant therapy based on breast cancer biology. The aim of this study is to assess
Externí odkaz:
https://doaj.org/article/544b82297ee64963ab227cd0de922dd8
Publikováno v:
Cancer Research. 83:P4-09
Background CDK4/6 inhibitors are the latest and highly specific CDK inhibitors approved for metastatic and early estrogen receptor (ER)-positive breast cancer patients, improving the survival outcomes. Prior preclinical research has indicated various
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a1f90cd75af15ee95087739f865f8171
https://doi.org/10.1158/1538-7445.sabcs22-p4-09-11
https://doi.org/10.1158/1538-7445.sabcs22-p4-09-11
Autor:
Naoko YASUMURA, Kazuya KURAOKA, Arisa KAN, Hiroki FUJISAWA, Akihisa SAITO, Daisuke YASUI, Hideo SHIGEMATSU, Kiyomi TANIYAMA
Publikováno v:
The Journal of the Japanese Society of Clinical Cytology. 61:10-17
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::46ed5649819f471b672d3c6d813c20ba
https://doi.org/10.5795/jjscc.61.10
https://doi.org/10.5795/jjscc.61.10
Publikováno v:
Medicine. 102:e33580
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b54d8cf610ccbe36a0cfed08c94f0f25
https://doi.org/10.1097/md.0000000000033580
https://doi.org/10.1097/md.0000000000033580
Publikováno v:
Cancer Research. 83:OT3-01
Background: The surgical treatment is the standard therapy for early breast cancer (EBC) after primary systemic therapy (PST). In more than half of HER2 positive (HER2(+)) breast cancer, pathological complete response (pCR) is achieved by PST with HE
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2344ac7e969f9810eb259dadd50df8d8
https://doi.org/10.1158/1538-7445.sabcs22-ot3-01-01
https://doi.org/10.1158/1538-7445.sabcs22-ot3-01-01
Publikováno v:
Japanese Journal of Clinical Oncology. 50:629-634
Breast cancer is highly sensitive to systemic therapy. High probability of pathological complete response suggests a clinical question that omitting surgery is an effective alternative to surgery in breast cancer showing clinical complete response to
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::80daa8871f24fbcb0b5a486dea973604
https://doi.org/10.1093/jjco/hyaa055
https://doi.org/10.1093/jjco/hyaa055
Publikováno v:
Nihon Rinsho Geka Gakkai Zasshi (Journal of Japan Surgical Association). 81:1049-1053
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4e06c4e292c429a78fca7d7b101f045f
https://doi.org/10.3919/jjsa.81.1049
https://doi.org/10.3919/jjsa.81.1049
Autor:
Noriko Goda, Shinsuke Sasada, Hideo Shigematsu, Norio Masumoto, Koji Arihiro, Hiroyoshi Nishikawa, Shimon Sakaguchi, Morihito Okada, Takayuki Kadoya
Purpose: FOXP3+ tumor-infiltrating lymphocytes (TILs) are prototypical immunosuppressive TILs in breast cancer. However, the FOXP3+ TIL subset of effector regulatory T cells (eTregs) cannot be detected with conventional immunohistochemical staining.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5aeffbc472c16ccb7fff03545ab7769e
https://doi.org/10.21203/rs.3.rs-1287664/v1
https://doi.org/10.21203/rs.3.rs-1287664/v1
Autor:
Tomoyuki Aruga, Nobuyasu Suganuma, Norikazu Masuda, Hiroji Iwata, Shinji Ohno, Hironori Haga, Eriko Tokunaga, Satoshi Morita, Shoichiro Ohtani, Hideo Shigematsu, Toshimi Takano, Kenichi Inoue, Tomomi Fujisawa, Katsumasa Kuroi, Naohito Yamamoto, Kenjiro Aogi, Masahiro Takada, Masakazu Toi, Kenichi Sakurai, Hiroko Bando
Publikováno v:
Cancers
Cancers, Vol 13, Iss 4008, p 4008 (2021)
Volume 13
Issue 16
Cancers, Vol 13, Iss 4008, p 4008 (2021)
Volume 13
Issue 16
We conducted the Neo-LaTH study in which patients were randomized to different lengths of neoadjuvant induction anti-HER2 therapy with lapatinib and trastuzumab followed by weekly paclitaxel plus the anti-HER2 therapy, and in estrogen receptor (ER)-p
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3455f6515f90188c8363b688e7132536
https://pubmed.ncbi.nlm.nih.gov/34439165
https://pubmed.ncbi.nlm.nih.gov/34439165